Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
Overview
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy is a scientific journal, published since 1993 in English. The journal's country of origin is United States and its primary focus areas are oncology, pharmacology and allergy & immunology.
Details
Details
Abbr.
J Immunother Emphasis Tumor Immunol
Start
1993
End
1996
Frequency
Bimonthly
p-ISSN
1067-5582
Country
United States
Language
English
Specialties
Oncology
Pharmacology
Allergy & Immunology
Pharmacology
Allergy & Immunology
Recent Articles
1.
Freedman R, Gibbons J, Giedlin M, Kudelka A, Kavanagh J, Edwards C, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):443-51.
PMID: 9041464
We determined in the peritoneal cavity (p.c.) of epithelial ovarian carcinoma patients during a 4-day treatment cycle of low-dose recombinant human interleukin-2 (rIL-2): (a) pharmacokinetics of IL-2, (b) endogenous cytokine...
2.
Vlock D, Andersen J, Kalish L, Johnson J, Kirkwood J, Whiteside T, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):433-42.
PMID: 9041463
The objective of this study was to study the antitumor, host toxicity, and immunomodulatory effects of recombinant interferon-alpha 2b (IFN) in patients with recurrent or metastatic squamous cell carcinoma of...
3.
Kageshita T, Naruse T, Hirai S, Horikoshi T, Nakagawa H, Tamaki K, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):428-32.
PMID: 9041462
In this study, we analyzed the frequencies of human leukocyte antigen (HLA) class I alleles in 110 Japanese patients with melanoma using serological methods, and compared such frequencies with clinical...
4.
Prewett M, Rockwell P, Rockwell R, Giorgio N, Mendelsohn J, Scher H, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):419-27.
PMID: 9041461
For prostate cancer, a correlation exists between overexpression of the epidermal growth factor receptor (EGFR) and poor clinical prognosis. In addition, late-stage metastatic disease is characterized by a change from...
5.
Gabrilovich D, Cunningham H, Carbone D
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):414-8.
PMID: 9041460
Mice bearing palpable tumors expressing a mutant p53 gene were treated with intravenous injection of mutant p53-specific peptide-pulsed dendritic cells (DCs). Control groups were treated with control peptide-pulsed DCs. All...
6.
Thompson R, Pardoll D, Jaffee E, Ewend M, Thomas M, Tyler B, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):405-13.
PMID: 9041459
Development of an effective immunotherapeutic approach for treatment of CNS tumors must take into account the unique anatomic and immunologic features of the brain. We explored the antitumor immune response...
7.
Miyajima J, Imai Y, Nakao M, Noda S, Itoh K
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):399-404.
PMID: 9041458
Erythropoietin production by renal cell carcinoma (RCC) is reported to be a potential marker for interleukin-2/interferon-alpha-responding tumor. We have investigated whether erythropoietin of RCC cells is involved in the immune...
8.
Akporiaye E, Panelli M
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):398.
PMID: 9041457
No abstract available.
9.
Brady M, Eckels D, Ree S, Schultheiss K, Lee J
J Immunother Emphasis Tumor Immunol
. 1996 Nov;
19(6):387-97.
PMID: 9041456
Constitutive expression of major histocompatibility complex (MHC) class II molecules is normally restricted to professional antigen-presenting cells (APCs) of the immune system, although it also occurs frequently in melanoma. Clinical...
10.
Lee J, Reveille J, Platsoucas C
J Immunother Emphasis Tumor Immunol
. 1996 Sep;
19(5):381-5.
PMID: 8941878
No abstract available.